Study on Dapagliflozin’s Impact on Heart Disease Outcomes

Introduction to Diabetes and Cardiovascular Risks

Diabetes currently affects over 415 million adults globally, with its prevalence continuing to rise. Individuals with diabetes face an elevated risk of complications, including cardiovascular disease, kidney disease, and heart disease. Therefore, it is crucial that diabetes medications not only manage blood sugar levels but also mitigate cardiovascular risks.

Dapagliflozin as an SGLT2 Inhibitor

Dapagliflozin is classified as an SGLT2 inhibitor and is utilized in diabetes treatment. While other SGLT2 inhibitors have shown positive cardiovascular outcomes, the effects of dapagliflozin specifically had not been thoroughly investigated. Researchers aimed to assess the cardiovascular safety and efficacy of dapagliflozin, publishing their findings in The New England Journal of Medicine.

Details of the DECLARE-TIMI 58 Trial

The DECLARE-TIMI 58 trial was conducted across 33 countries and included over 17,000 participants aged 40 and older. These individuals had type 2 diabetes along with either cardiovascular disease or multiple cardiovascular risk factors. Participants were randomly assigned to receive either 10 mg of dapagliflozin daily or a matched placebo. Clinical and safety assessments occurred during in-person visits every six months, with a median follow-up duration of 4.2 years. The primary safety outcomes measured included major adverse cardiovascular events (MACE) and cardiovascular-related death or hospitalization due to heart failure.

Findings on Cardiovascular Risk Factors

The research revealed that dapagliflozin positively influenced various cardiovascular risk factors when compared to the placebo group. Participants receiving dapagliflozin experienced greater reductions in blood sugar levels, weight, and blood pressure. Although there was no significant decrease in the incidence of cardiovascular events such as heart attacks or strokes in patients with heart disease or risk factors, hospitalization rates due to heart failure were significantly lower in the dapagliflozin group. This benefit was evident across a diverse patient population.

Assessment of Heart Failure and Other Risks

Notably, most trial participants did not have a prior history of heart failure, highlighting dapagliflozin’s potential in preventing new cases of heart failure. There were no notable differences in overall mortality or cardiovascular-related deaths between the two groups. However, the dapagliflozin group did report a higher incidence of diabetic ketoacidosis, although this was considered rare. Additionally, rates of genital infections were elevated in the dapagliflozin cohort compared to the placebo. While other SGLT2 inhibitors have raised concerns regarding potential risks for strokes, amputations, or fractures, this study found no evidence indicating that dapagliflozin increased these risks.

Conclusion on Dapagliflozin’s Safety Profile

The findings from the DECLARE-TIMI 58 trial suggest that dapagliflozin for diabetes treatment is comparable to placebo regarding the risk of major adverse cardiovascular events and cardiovascular death. Furthermore, dapagliflozin was associated with a significantly reduced hospitalization rate due to heart failure among a wide range of patients with type 2 diabetes.

References

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., . . . Sabatine, M. S. (2018). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. doi:10.1056/nejmoa1812389

Murphy, M. (2018, November 10). Diabetes drug prevents heart failure. Retrieved from https://www.eurekalert.org/pub_releases/2018-11/bawh-ddp111018.php